Phathom Pharmaceuticals, Inc.PHATNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +4249.56% | +1391.58% | +439.36% | +202.74% | +94.12% |
| Gross Profit Growth | +7733.03% | +1568.57% | +479.44% | +209.47% | +93.19% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +24.00% | +23.29% | +23.75% | +13.57% | +2.64% |
| Weighted Average Shares Diluted Growth | +24.00% | +23.29% | +23.75% | +13.57% | +2.64% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +2270.01% | +837.46% | +371.22% | +165.01% | +101.38% |
| Inventory Growth | +165.56% | +117.15% | +57.60% | +16.07% | +72.01% |
| Asset Growth | -8.55% | -17.47% | -21.65% | -37.92% | -31.53% |
| Book Value per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Debt Growth | +299.16% | +20.38% | +13.45% | -99.48% | -99.51% |
| R&D Expense Growth | -35.91% | -2.61% | +23.05% | -19.16% | -12.70% |
| SG&A Expenses Growth | +34.98% | +52.35% | +12.44% | -32.25% | -36.92% |